Welcome To Campus Sanofi Singapore

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

Systematic review shows Beyfortus^® reduces RSV hospitalizations by 83% and ICU admissions by 81% in real-world infant immunization programs.

Chronic spontaneous urticaria (CSU) creates substantial patient burden through persistent wheals, angioedema, and debilitating itch that severely disrupts daily functioning. Emerging evidence positions type 2 inflammation as a driver of CSU pathogenesis. IL-4 plays a particularly crucial role by stimulating excessive IgE production and promoting formation of IgG anti-IgE autoantibodies—both pathways that trigger mast cell degranulation and subsequent CSU symptoms. This mechanistic understanding has opened therapeutic opportunities targeting type 2 inflammatory pathways for patients who remain symptomatic despite standard antihistamine therapy.​

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Citation: Geba et al. Journal of Allergy and Clinical Immunology 2025;Vol.151: 756-766

Rare Disease Day raises awareness for the 300 million people worldwide living with a rare disease, along with their families and carers. Over 6,000 rare diseases are characterized by a wide range of conditions and symptoms that can vary not only between diseases but also among individuals with the same condition. Take the opportunity to support equitable access to diagnosis, treatment, healthcare, social support for those affected by rare diseases.